TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
Authors
Keywords
-
Journal
ONCOGENE
Volume 34, Issue 16, Pages 2138-2144
Publisher
Springer Nature
Online
2014-06-09
DOI
10.1038/onc.2014.156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Luis Paz-Ares et al. Journal of Thoracic Oncology
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode
- (2013) B Gillissen et al. Cell Death & Disease
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization
- (2012) Daniele Lecis et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The peritoneal tumour microenvironment of high-grade serous ovarian cancer
- (2012) D Andrew Leinster et al. JOURNAL OF PATHOLOGY
- A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells
- (2012) Eleonora Petrucci et al. PLoS One
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types
- (2010) Paula J. Kaplan-Lefko et al. CANCER BIOLOGY & THERAPY
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors
- (2010) N. M. Haynes et al. JOURNAL OF IMMUNOLOGY
- The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells
- (2010) N Goncharenko-Khaider et al. ONCOGENE
- Is TRAIL the holy grail of cancer therapy?
- (2009) Thomas Newsom-Davis et al. APOPTOSIS
- Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo
- (2008) M. Vogler et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now